Salarius Pharmaceuticals (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company’s lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet medical need, with an ongoing clinical study in Ewing sarcoma and a clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT)
Location: United States, Texas, Houston
Employees: 11-50
Founded date: 2011
Investors 7
Mentions in press and media 7
| Date | Title | Description |
| 16.02.2023 | Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas | - |
| 22.04.2022 | Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering | HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that it has ent... |
| 28.09.2021 | Salarius Pharmaceuticals : Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas | HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic an... |
| 28.09.2021 | Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas | Salarius Pharmaceuticals, Inc. announced the receipt of a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payment is part of a non-dilutive grant that was originally a... |
| 14.07.2021 | Salarius Pharmaceuticals : Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit | HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, an... |
| 04.03.2021 | Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock | HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, t... |
| - | VisionTech Angels Reap Rewards as Salarius Pharmaceuticals, Inc. Completes Merger with Flex Pharma | INDIANAPOLIS, Ind., (September 17, 2019) – – When Salarius Pharmaceuticals (Nasdaq: SLRX) President and Chief Executive Officer David Arthur rang the opening bell at Nasdaq in New York City on July 30, recognizing the company’s successful m... |